One-Trial Drugs? FDA Drops Safeguard

The FDA just made it easier to approve new drugs with less human testing up front—replacing a decades-old safeguard with a faster default.

Quick Take

The FDA will no longer expect two pivotal clinical trials as the default for approving new drugs.
Under the new policy, one “adequate and well-controlled” trial can be enough if backed by “confirmatory evidence.”
FDA leaders say modern biology, biomarkers, trial designs, and statistics can reduce the need for duplicate pivotal trials.
Critics and some experts warn the shift raises the stakes for post-market monitoring and patient safety oversight.
The change continues a long trend toward faster approvals and more use of expedited pathways in recent decades.

FDA Rewrites the Default Standard for Drug Approval

FDA Commissioner Marty Makary and FDA vaccine chief Vinay Prasad announced a major policy shift in mid-February 2026: the agency will now default to approving many new drugs based on one pivotal clinical trial rather than two. The new approach still requires an “adequate and well-controlled” study, but it allows sponsors to rely on additional “confirmatory evidence” to support efficacy instead of running a second large trial.

FDA leadership framed the change as a modernization of drug review rather than an abandonment of science. Their stated rationale centers on advances in biology and trial methodology that can increase confidence in results without duplicating pivotal studies. Under the policy as described, confirmatory evidence can include mechanistic data, evidence from related indications, or animal models. The FDA also positioned this as a broad, default standard—distinct from older “expedited” exceptions.

Why Two Trials Became the Gold Standard—and What Replaces It

The expectation of two independent pivotal studies traces back to the early 1960s, when Congress required “adequate and well-controlled investigations” to prove a drug works. Over time, FDA practice commonly treated that language as a two-trial safeguard to reduce the risk that a single positive outcome was a statistical fluke. The new policy keeps the statutory foundation but changes how the FDA interprets what’s usually needed to meet it.

In practical terms, the new default shifts part of the proof burden away from replication and toward supporting evidence that may not come from large, randomized human trials. That may speed access for patients—especially where diseases are serious and options are limited—but it also compresses the pre-approval record doctors and families often rely on when weighing benefits versus risks. The FDA has not, in the available reporting, provided detailed case-by-case guardrails.

A Long March Toward Faster Approvals Didn’t Start in 2026

Research cited in the available coverage shows the FDA had already been moving away from routine two-trial approvals for years. One analysis reported that approvals backed by at least two pivotal trials declined from 80.6% in 1995–1997 to 52.8% in 2015–2017. In that same era, expedited programs became common, with most new drugs benefiting from at least one faster-review pathway by 2018, reflecting a broader institutional push to accelerate timelines.

Those older pathways emerged from real crises and political pressures. The Accelerated Approval program was created in 1992 amid the HIV/AIDS epidemic, and the 1993 Prescription Drug User Fee Act brought industry-paid fees tied to review timelines. The new policy differs because it aims to make a reduced pre-approval evidence package the norm, not a limited exception. That distinction matters because “default” tends to become the baseline expectation for sponsors.

What This Means for Patients: Faster Access, More Pressure After Approval

Supporters highlight obvious upsides: fewer pivotal trials can mean lower development costs and shorter timelines, allowing new treatments to reach patients sooner. For families dealing with life-threatening conditions, time is not an abstract policy variable. At the same time, reducing the amount of replicated, pre-approval human evidence can increase uncertainty around efficacy and safety—especially for drugs that look promising in one study but might not hold up across broader populations.

The trade-off is likely to place more weight on post-market surveillance and real-world evidence to catch problems that might have been detected earlier with a second pivotal trial. That approach can work only if monitoring is strong, transparent, and timely. The available reporting also notes controversy significant enough that at least one high-ranking FDA official left the agency over the shift—an indicator of serious internal disagreement even if detailed objections were not fully published.

What Conservative Voters Should Watch Next

Washington has a long history of agencies expanding their discretion through “guidance” and policy reinterpretations that rarely get a full, plain-English debate. The FDA’s one-trial default may prove beneficial for rapid innovation, but it also concentrates decision-making power inside federal bureaucracy while shifting more risk downstream to patients, doctors, and insurers. The key questions now are how the FDA defines “confirmatory evidence,” how strictly it applies it, and how it enforces follow-up once drugs hit the market.

FDA Dropping Requirement For 2 Studies For New Drug Approvals https://t.co/MiEhsTOesX

— zerohedge (@zerohedge) February 21, 2026

For Americans already skeptical after years of institutional overreach and shifting expert consensus, the credibility of the system will depend on transparency. If approvals accelerate without clear public standards and strong monitoring, confidence will erode regardless of political affiliation. If the FDA pairs faster approvals with rigorous, visible post-market accountability, the new standard could be judged on outcomes rather than slogans. For now, the policy is official, broad, and consequential—and it deserves close scrutiny.